(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 7.96% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.69%.
Maxcyte's revenue in 2025 is $38,627,000.On average, 2 Wall Street analysts forecast MXCT's revenue for 2025 to be $4,421,356,466, with the lowest MXCT revenue forecast at $4,378,945,373, and the highest MXCT revenue forecast at $4,463,767,559.
In 2026, MXCT is forecast to generate $5,333,194,970 in revenue, with the lowest revenue forecast at $5,205,961,690 and the highest revenue forecast at $5,460,428,250.